Female Pelvic Medicine & Reconstructive Surgery:
Brubaker, L.1; the PFDN2
1OG, Loyola, Maywood, IL; 2for the, Pelvic Floor Disorders Network, Bethesda, MD
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS: Linda Brubaker:Allergan:Research Funding:Investigator; Pfizer:Research Funding:Investigator;Pfizer:Honorarium:Research Consultant
Surgeons are aware that the arbitrarily adopted stages of the POP-Q system do not correlate well with symptoms or differentiate clinically important subgroups. POP-Q stage is an ordinal (rather than continuous) variable, which has statistical limitations as a surgical outcome measure. We defined three continuous summary scores, based on POP-Q measures, to describe support loss and assessed their correlation with prolapse symptoms.
MATERIALS AND METHODS:
We used baseline data from 1141 subjects in 3 randomized trials of the Pelvic Floor Disorders Network (CARE 322, OPUS 380, ATLAS 439) to test the utility of three support loss scores: SL (Support Loss) = (TVL + C) + (Aa + 3) + (Ap + 3) + (Ba + 3) + (Bp + 3); SL3 = (TVL + C) + (Ap + 3) + (Bp + 3); and SLmax = location of single most distal point. Zero is the theoretical lower limit of SL and SL3 and −3 is the limit for SLmax, and represent perfect support. Higher values of SL measures represent greater support loss. Each support loss measure was correlated with POP-Q stage, total scores for responses to the Pelvic Organ Prolapse Distress Inventory (POPDI) and the Pelvic Organ Prolapse Impact Questionnaire (POPIQ), and responses to questions 4 (“usually have a sensation of bulging or protrusion”) and 5 (“usually have a bulge or something falling out seen/felt”) of the Pelvic Floor Distress Inventory (PFDI). Two-year CARE data were used to assess utility of these support loss measures for describing anatomical outcomes.
All POP-Q stages were represented within the 1141 subjects: Stage 0 (4%), 1 (18%), 2 (29%), 3 (41%), 4 (8%). Symptomatic subjects were moderately (11%) or quite often (32%) bothered. Subjects had a wide range of support loss scores (mean [range]): SL [18.1 (0 to 60)], SL3 [10.7 (0 to 41)] and SLmax [1.5 (−3 to 12)]. Support loss scores were comparable to POP-Q stage with respect to correlation with baseline prolapse symptoms (Table 1).
The anatomic improvement in the CARE population is displayed using continuous support loss measures and POP-Q stage (Table 2). However, anatomic change, as measured by support loss or POP-Q stage, was not well correlated with prolapse symptom improvement.
Summary measures of support loss that more closely correlate with prolapse symptoms are desirable. These new support loss measures have a statistical advantage as continuous variables and may improve the transparency of surgical outcome reporting, augmenting the current POP-Q staging.